X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Molecular Therapy Nucleic Acids

期刊標題檢索 MOL THER NUCL A 最新評論: 3 points for distribution and 10 points for return, and it is still no... (2024-04-17)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Molecular Therapy Nucleic Acids]您好,您是該頁面的第 116713 位訪客。

期刊簡介
期刊名稱Molecular Therapy Nucleic Acids Molecular Therapy Nucleic Acids
LetPub Score
7.4
51 ratings
Rate

Reputation
8.1

Influence
6.6

Speed
9.1

期刊簡稱MOL THER NUCL ACIDS
ISSN2162-2531
h-index43
CiteScore
CiteScoreSJRSNIPCiteScore Rank
15.401.8491.136
Subject fieldQuartilesRankPercentile
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Drug Discovery
Q18 / 157
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Molecular Medicine
Q116 / 178

自引率 (2023-2024)1.50%自引率趨勢
掲載範囲
Molecular Therapy — Nucleic Acids publishes research targeted to the advances in nucleic acid-based therapeutics to treat and/or correct genetic and acquired disease. Subject areas include: development of therapeutics based on nucleic acids and their derivatives, vector development and design for the delivery of RNA-based therapeutics, and applications of gene-modifying agents.
官方網站http://www.nature.com/mtna/index.html
在線稿件提交http://mts-mtna.nature.com/cgi-bin/main.plex
開放訪問Yes
出版商Cell Press
主題領域MEDICINE, RESEARCH & EXPERIMENTAL
出版國/地區UNITED STATES
發行頻率
創刊年0
每年文章數233每年文章數趨勢
黃金OA百分比90.82%
OA Related Info
APC: Yes( USD3900; )
APC waiver:Check Notes
Other charges: No
Keywords: vector development、rna based therapeutics、gene modifying agents
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
MEDICINE, RESEARCH & EXPERIMENTALSCIEQ125/189
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2162-2531%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 20 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Molecular Therapy Nucleic Acids】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    CA-A CANCER JOURNAL FOR CLINICIANSH-index: 144

    CiteScore: 873.20
    NATURE REVIEWS DRUG DISCOVERYH-index: 289

    CiteScore: 137.40
    LANCETH-index: 700

    CiteScore: 148.10
    NEW ENGLAND JOURNAL OF MEDICINEH-index: 933

    CiteScore: 145.40
    Nature Reviews Clinical OncologyH-index: 127

    CiteScore: 99.40
    Nature Reviews Disease PrimersH-index: 48

    CiteScore: 76.70
    NATURE REVIEWS CANCERH-index: 396

    CiteScore: 111.90
    NATURE REVIEWS IMMUNOLOGYH-index: 351

    CiteScore: 93.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONH-index: 622

    CiteScore: 48.20
    World PsychiatryH-index: 70

    CiteScore: 64.10
    學科內最受檢索的期刊 頁面查看次數
    BIOMATERIALS715879
    MEDICINE651860
    JOURNAL OF ETHNOPHARMACOLOGY529554
    Frontiers in Pharmacology517623
    BIOMEDICINE & PHARMACOTHERAPY499576
    Journal of Materials Chemistry B476455
    Frontiers in Immunology466265
    COMPUTERS IN BIOLOGY AND MEDICINE426253
    COLLOIDS AND SURFACES B-BIOINTERFACES420376
    Frontiers in Oncology419899
  •  

    Molecular Therapy Nucleic Acids Molecular Therapy Nucleic Acids
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/17)
  [Molecular Therapy Nucleic Acids] 的評論撰寫評論
作者: 碧桃幻露


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-17 19:26:08 評論於
3 points for distribution and 10 points for return, and it is still not a foul
(0) 讚! | 碧桃幻露

作者: 魔都小柔


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-11 21:13:30 評論於
On July 18, 2023, the First Affiliated Hospital of Zhejiang University updated the "List of Journals Not Recommended for Submission". The hospital has set up a "List of Journals Not Recommended for Submission" based on the regularly published "International Journal Alert List" by the Chinese Academy of Sciences Literature and Information Center, and updates it dynamically. Starting from July 19, 2023, papers submitted to the following journals will not be reimbursed for page charges
(0) 讚! | 魔都小柔

作者: 南风慕夏


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-20 15:59:03 評論於
Hello, does this magazine require the upload of primary data?
(0) 讚! | 南风慕夏

作者: 南风慕夏


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-06-30 10:26:01 評論於
Is it possible to upload revised manuscripts after pre-acceptance?
(0) 讚! | 南风慕夏

作者: 东京志燕


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-05-24 16:28:26 評論於
Review speed: 2.0 | Submission hit rate: 5.0 
Experience sharing: After revising for 6 months and satisfying most reviewers' comments, the paper was rejected by a new foreign editor. It was a huge setback, everyone, run fast!
(0) 讚! | 东京志燕

作者: 北海俊晤


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-05-07 21:41:46 評論於
Research focus: RNA; Cell biology experience sharing: Have you submitted any papers recently? I would like to know more about the review process and timeline. Thank you
(0) 讚! | 北海俊晤

作者: luofeiyu


領域: 医学
審稿時間: 12.0 month(s)
結果: 直接被接受


撰寫評論

2023-01-03 11:59:02 評論於
These trash magazines have also been classified into Zone 1.
(206) 讚! | luofeiyu

作者: 烈焰以岚


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-27 22:08:32 評論於
The warning will be removed in the latest version this year... The quality of the articles published in the magazine recently is very good, showing clear progress
(0) 讚! | 烈焰以岚

作者: 烈焰以岚


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-27 09:20:26 評論於
Congratulations
(0) 讚! | 烈焰以岚

作者: 不灭心香


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-11 18:22:54 評論於
Review speed: 3.0 
Emphasis on research direction: RNA 
Neuroscience Experience Sharing: Submitted on November 31, 2021, finally accepted on October 12, 2022, taking more than 11 months... The reviewers were very thorough and responsible, although most of the revisions were minor details, it was still very painful
(0) 讚! | 不灭心香

作者: Sara Lincoln


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-10 15:55:31 評論於
This magazine has almost retracted all the articles from the paper factory. It is estimated that there will be no more warnings next year or the year after
(0) 讚! | Sara Lincoln

作者: Lucy Larkin


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-24 17:31:36 評論於
It is not surprising that this journal has been warned, as many articles produced by paper mills have been published in the past few years. However, there has been some improvement in the magazine this year
(0) 讚! | Lucy Larkin

作者: 震山今雨


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-19 08:15:25 評論於
This journal only has less than 3% self-citation, with less than 500 articles published each year, and the proportion of Chinese authors is not more than 25%. China's population accounts for 20% of the world's population, so what criteria should be used for early warning? If the warning is based solely on the proportion of Chinese authors, then what about the many domestic SCI journals with a 90% proportion? Why aren't they warned? What about other publishers who have many journals like Oncology Reports? Why aren't they warned?
(0) 讚! | 震山今雨

作者: Sara Lincoln


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-30 22:36:13 評論於
Have you received it?
(0) 讚! | Sara Lincoln

作者: Sara Lincoln


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-30 20:11:49 評論於
Did you wrap up your article at the end?
(0) 讚! | Sara Lincoln

作者: 天神院志敏


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-15 23:20:07 評論於
The highly alert journal of the Chinese Academy of Sciences, there is no need to discuss
(0) 讚! | 天神院志敏

作者: 虚徒之山


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-14 09:46:53 評論於
Review Speed: 6.0 | Submission Acceptance Rate: 25.0
Sharing Experience: I have been accepted by CAS, so I won't introduce it
(0) 讚! | 虚徒之山

作者: 白云蕴秀


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-12 17:48:34 評論於
In the end, after spending four months with the editor for submission, one month for review, one month for minor revisions after receiving feedback, and two months for final review, the paper was finally accepted. Though the process was long, it ended with acceptance
(0) 讚! | 白云蕴秀

作者: 不灭心香


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-09 17:34:04 評論於
Research focus: Molecular therapy; Neuro experience sharing: After the second review, it has been 1 and a half months and the decision has been in process for 2 days. Does this mean the paper is going to be rejected?
(0) 讚! | 不灭心香

作者: 霹雳鸿光


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-05 10:41:23 評論於
Submitting Falsified Data to Chinese Journals
(0) 讚! | 霹雳鸿光

作者: Quinn Pullan


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-11 11:45:55 評論於
Garbage
(0) 讚! | Quinn Pullan

作者: 平原代芹


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-09 18:19:22 評論於
Review Speed: 2.0 | Submission Acceptance Rate: 25.0
Experience Sharing: Very slow, typically takes over 9 months
(0) 讚! | 平原代芹

作者: 平原代芹


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-09 13:49:42 評論於
That's you, not mine
(0) 讚! | 平原代芹

作者: 深渊绍辉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-01-27 15:14:27 評論於
oncology reports like this are still unpredictable. This warning list is just silly
(0) 讚! | 深渊绍辉

作者: 明冠文成


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-01-21 15:27:42 評論於
I'll be back in about two weeks
(0) 讚! | 明冠文成

首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/17)

開始撰寫 [Molecular Therapy Nucleic Acids] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*